The Food and Drug Administration (FDA) is offering a funding opportunity titled "Novel approaches to support therapeutic development in ultra-rare cancers," aimed at exploring innovative methods to enhance therapeutic development for these specific cancer types. This initiative is particularly focused on small businesses, which are encouraged to apply for this cooperative agreement that falls under the discretionary category of funding. The program is significant as it addresses the critical need for advancements in treatment options for ultra-rare cancers, which often lack sufficient research and development support. Interested applicants can reach out to Patrick Johnson, Grants Management Specialist, at patrick.johnson@fda.hhs.gov or call 301-796-0154 for further information. The expected number of awards is two, with no cost-sharing requirement, and the opportunity is set for the fiscal year 2026.